Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease - Concepedia

Concepedia

Publication | Open Access

Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease

DOI Full Paper Access

284

Citations

14

References

2018

Year

Cem Gabay, Bruno Fautrel, Jürgen Rech, François Spertini, Eugen Feist, Ina Kötter, É. Hachulla, Jacques Morel, Thierry Schaeverbeke, M. Hamidou,

Annals of the Rheumatic Diseases

References

	Year	Citations

Page 1